102-LB: Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients during COVID-19 Pandemic in Argentina
| Autor: | Matias Castro, Adrián Proietti, Alejandro Daín, María Laura Kabakian, Mariela I. Echenique, Marcela Raggio, Marcial A. Angós, Antonio Saleme, Graciela Rubin, Luis Grosembacher, María Pía Santucci, Andrea Daghero, Maria Paula Paz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty Type 1 diabetes education.field_of_study Coronavirus disease 2019 (COVID-19) business.industry Endocrinology Diabetes and Metabolism Population medicine.disease Spouse Diabetes mellitus Pandemic Internal Medicine medicine Observational study business education Glycemic |
| Zdroj: | Diabetes. 70 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | Background and Aims: Despite recent technological advances, optimal glycemic control remains a challenge in people with type 1 diabetes (T1D). Hybrid closed loop (HCL) systems with automated algorithm-derived adjustment of basal insulin delivery, aims to improve glycemic control without adding additional therapy burden or educational investments. Aim: To evaluate the effectiveness of HCL system in Latin American subjects with T1D and who received a completely virtual training. Methods: Prospective observational data analysis that included consecutive patients with T1D that initiated treatment with MiniMed™ 670G system in Argentina. Baseline and follow up visits at days 28, 90 and 180 were carried out and data was downloaded from Carelink™ Personal at each visit. Patient training and follow-up were performed completely virtual through video conference. Results: A total of 104 patients were included, age: 32.8 ± 17.2 (range 8-77). Subjects were previously on MDI+SMBG (26%), MDI+isCGM (12.5%), CSII+SMBG (9.6%), CSII+isCGM (2.9%), and SAP-TS (49%). Baseline GMI was 7.3 ± 0.8%. Time in range (TIR) 70-180 mg/dl significantly increased regardless of prior therapy from 62.1±14.8 % at baseline to 74.6±8.6 %, 74.2±9.8 % and 74.3±9.6 % at days 28, 90 and 180 respectively (p Conclusions: Our findings confirm that the use of MiniMed™ 670 System allows patients to achieve glycemic control within recommended targets in a non-selected population in Argentina. Virtual education appears to be suitable for patient training on HCL therapy during current COVID-19 pandemic situation. Disclosure A. E. Proietti: None. M. P. Santucci: None. M. Castro: Employee; Spouse/Partner; Medtronic. A. Daghero: Employee; Spouse/Partner; Medtronic. L. A. Grosembacher: None. M. A. Angós: None. A. Dain: None. M. I. Echenique: None. M. L. Kabakian: Speaker’s Bureau; Self; Abbott, Medtronic. M. P. Paz: Speaker’s Bureau; Self; Medtronic. M. Raggio: Speaker’s Bureau; Self; Abbott, Medtronic, Roche Diabetes Care. G. B. Rubin: None. A. Saleme: Advisory Panel; Spouse/Partner; Abbott Diabetes, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|